title: The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation.
abstract: 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid (PACA), pharmacological inhibitor of phospholipase A(2) (PLA(2)), inhibits epinephrine-stimulated thromboxane production in human platelets. In this study, we investigated the effect of PACA on meiotic maturation individually in stages V and VI oocytes. PACA prevented the maturation in stage V but merely delayed the process in stage VI oocytes. This was associated with the strong inhibition of Mos synthesis at both stages. Besides, PACA-induced inhibition of MAPK activation was evident in stage V but not in stage VI oocytes. PACA also inhibited the activation of Cdc2 kinase (Cdc2) in stage V but merely delayed the process in stage VI oocytes. Furthermore, 5 microM and higher concentrations of PACA completely inhibited the activation of MAPK and Cdc2 only in stage V, not in stage VI, oocytes. Moreover, we propose PACA as a new tool for the study of Xenopus oocyte maturation, which can also play a unique role for the studies of the stage-specific activation of MAPK and Cdc2.
authors.affiliation: Division of Pathological Biochemistry, Department of Biomedical Sciences, School of Life Sciences, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago 683-8503, Japan.
authors.forename: Azharul
authors.initials: A
authors.lastname: Islam
authors.forename: Yoko
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Kosaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshitome
authors.forename: Isamu
authors.initials: I
authors.lastname: Sugimoto
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamada
authors.forename: Ellen
authors.initials: E
authors.lastname: Shibuya
authors.forename: George F
authors.initials: GF
authors.lastname: Vande Woude
authors.forename: Eikichi
authors.initials: E
authors.lastname: Hashimoto
mesh_terms: D062365:Aminobenzoates / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence; D016203:CDC2 Protein Kinase / Q000378:metabolism*; D002723:Chlorobenzoates; D002934:Cinnamates / Q000494:pharmacology*; D005260:Female; D008540:Meiosis; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008969:Molecular Sequence Data; D009865:Oocytes / Q000166:cytology / Q000201:enzymology / Q000254:growth & development*; D009866:Oogenesis / Q000502:physiology*; D017231:Proto-Oncogene Proteins c-mos / Q000378:metabolism; D014981:Xenopus; D029867:Xenopus Proteins / Q000378:metabolism; D062367:ortho-Aminobenzoates
chemical_list: D062365:Aminobenzoates; D002723:Chlorobenzoates; D002934:Cinnamates; D029867:Xenopus Proteins; D062367:ortho-Aminobenzoates; C060048:2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid; C495329:Mos protein, Xenopus; D017231:Proto-Oncogene Proteins c-mos; D016203:CDC2 Protein Kinase; D020928:Mitogen-Activated Protein Kinases